Eli Lilly announces a record $5.3 billion investment to expand its Indiana manufacturing site, bringing the total commitment to $9 billion. The site will produce tirzepatide, the key ingredient in Zepbound and Mounjaro, with drug production expected to start in 2026. The expansion aims to boost the supply of weight-loss and diabetes treatments.
GLP-1 #weightloss medicines are expensive #T2D #obesity -can you help pay for them by investing in $OZEM a new ETF focused on weight loss companies? https://t.co/yjBoUQlFZ2 @anna_gle @CNBC @roundhill https://t.co/IoVrN6F12e
GLP-1 #weightloss medicines are expensive #T2D #obesity -can you help pay for them by investing in $OZEM a new ETF focused on weight loss companies? @jimcramer https://t.co/urLdfo5Tjq
WATCH: Some healthcare analysts have raised their annual sales forecasts for weight-loss drugs by around 50% to about $150 billion by the early 2030s https://t.co/w5mZXx924W https://t.co/VrYnHaqplJ
Some healthcare analysts have raised their annual sales forecasts for weight-loss drugs by around 50% to about $150 billion by the early 2030s https://t.co/KEWZhjgt3C https://t.co/Objtv2CSq9
WATCH: As millions seek access to weight-loss drugs from Novo Nordisk and Eli Lilly, increasing supplies, possible wider usage and a growing number of would-be rivals are leading some experts to raise annual global sales forecasts for the treatments https://t.co/w5mZXx8ufo https://t.co/RRcivkWFT2
As millions seek access to weight-loss drugs from Novo Nordisk and Eli Lilly, increasing supplies, possible wider usage and a growing number of would-be rivals are leading some experts to raise annual global sales forecasts for the treatments https://t.co/KEWZhjh0Ta https://t.co/uUr9YPrvQN
$VKTX $LLY $NVO Analysis-Weight-loss drug forecasts jump to $150 billion as supply grows We gonna see multiple companies to profit huge over next so many years to come This market is gonna continue to explode because we humans not gonna change our habits overnight
Sooner or later market will realize how $VKTX has the edge over others in safety which is very crucial for obesity drugs adoption rates
🚨 $150 BILLION MARKET FOR WEIGHT-LOSS DRUGS? Forecasts for weight-loss drugs from Novo Nordisk and Eli Lilly surge to $150 billion by early 2030s. Despite $1,000+ monthly costs, many pay out-of-pocket or use coupons. Global obesity drug spending hit $24 billion last year and… https://t.co/kwVMa5bW2Z https://t.co/cBV2ES6ps8
Eli Lilly $LLY will invest an additional $5.3B in its Indiana plant to expand the production of its weight loss drug Zepbound and diabetes treatment Mounjaro, bringing its total investment to $9B.
Novo Nordisk says it keeps about 60% of the price of the weight loss drugs Ozempic and Wegovy that it sells in the US https://t.co/HiMUlAMSwl via @business
Novo Nordisk says it keeps about 60% of the price of the weight loss drugs Ozempic and Wegovy that it sells in the US https://t.co/mK4kAgAvY2
Weight-loss drug forecasts jump to $150 billion as supply grows https://t.co/BxL8hB6lCk https://t.co/BxL8hB6lCk
$NVO vs $LLY Novo Nordisk’s anti-obesity medication, Wegovy, helped patients lose about 10% to 15 % of their body weight , while Eli Lilly’s Zepbound resulted in a loss of around 16% to 23% via @CNBC
$NVO vs $LLY Novo Nordisk’s anti-obesity medication, Wegovy, helped patients lose about 10% to 15 % of their body weight , while Eli Lilly’s Zepbound resulted in a loss of around 16% to 23%
Eli Lilly to invest another $5.3 billion in Indiana plant to expand Mounjaro, Zepbound supply https://t.co/F5MBX3HEo4
Eli Lilly beefs up plan to expand manufacturing for popular drugs Zepbound, Mounjaro https://t.co/sX7T19KipO
Eli Lilly to spend $5.3 billion to boost Zepbound, Mounjaro manufacturing https://t.co/72MFbaOa4s
Eli Lilly To Invest Record $5.3B To Expand Plant That Manufactures Weight-Loss Drugs https://t.co/dUtYv4Gp6T
Eli Lilly is investing another $5.3 billion in an Indiana manufacturing plant to boost supply of Zepbound, Mounjaro and other medicines. https://t.co/LUAYmhs56L https://t.co/xc9cRZ1HJ4
Eli Lilly will spend more than $5 billion to expand an Indiana manufacturing site and eventually make more doses of its popular weight-loss and diabetes treatments, Zepbound and Mounjaro. https://t.co/2013Kpp0hs
.@EliLillyandCo expands plans for new Indiana site that will make #tirzepatide, the main ingredient in #Zebound & #Mounjaro. With the $5.3b investment, Lilly’s financial commitment to site is now $9b. It’s expected to start drug production in 2026. https://t.co/Q2xyWnVF9f $LLY
$LLY | Eli Lilly Makes Largest Manufacturing Investment In Its History To Boost Production For Antidiabetic And Weight Loss Meds The expansion will enhance Lilly's capacity to manufacture tirzepatide, an active pharmaceutical ingredient for Zepbound and Mounjaro. Eli Lilly… https://t.co/1fIXsDXBq8
Eli Lilly says its capital commitment to its new Indiana site is the largest manufacturing investment in the company’s history. The site will make tirzepatide, the active pharmaceutical ingredient in both Zepbound and Mounjaro. https://t.co/bqTN9peBAu